Waiting for the Changes After the Adoption of Steatotic Liver Disease

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2023 Sep 6

PMID 37670441

Authors

Eileen L Yoon

Dae Won Jun

Affiliations

Soon will be listed here.

Abstract

Steatotic liver disease was suggested as an overarching term encompassing various etiologies of hepatic steatosis. Experts from multinational liver societies went through the Delphi process, including four rounds of surveys, and consented to adopt a new nomenclature and definition instead of the conventional nonalcoholic fatty liver disease (NAFLD). This was to improve the understanding of the patients and primary care physicians, with an explanation of the pathophysiology in the name of the disease. Also, it could minimize the stigmatization of patients by using the histological neutral term "steatosis" instead of "fatty". Herein, we will discuss the changes and continuity between the two nomenclatures, metabolic dysfunction-associated steatotic liver disease (MASLD) and NAFLD, as well as the challenges to MASLD which need to be addressed in future.

Citing Articles

A novel 11β-HSD1 inhibitor ameliorates liver fibrosis by inhibiting the notch signaling pathway and increasing NK cell population.

Kim J, Kim Y, Bae J, Laurel Yoon E, Kim H, Lee S Arch Pharm Res. 2025; 48(2):166-180.

PMID: 39954198 DOI: 10.1007/s12272-025-01534-4.

Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis.

Ryu G, Laurel Yoon E, Kim W, Won Jun D Diagnostics (Basel). 2025; 15(3).

PMID: 39941272 PMC: 11817575. DOI: 10.3390/diagnostics15030342.

Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy.

Xu J, Li Y, Feng Z, Chen H Cells. 2025; 14(3).

PMID: 39937012 PMC: 11816580. DOI: 10.3390/cells14030221.

Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults.

Lee J, Han C, Lee D, Sung P, Bae S, Yang H Gut Liver. 2024; 19(1):116-125.

PMID: 39639749 PMC: 11736320. DOI: 10.5009/gnl240323.

Establishment and characterization of mouse metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma organoids.

Kim S, Jeong N, Park J, Noh H, Lee J, Yu S Sci Rep. 2024; 14(1):27460.

PMID: 39523389 PMC: 11551198. DOI: 10.1038/s41598-024-78963-6.

References

Park H, Yoon E, Kim M, Lee J, Kim J, Cho S . Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era. Hepatol Res. 2021; 52(3):247-254. DOI: 10.1111/hepr.13737. View

Sookoian S, Pirola C . Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response. Clin Mol Hepatol. 2022; 29(Suppl):S184-S195. PMC: 10029961. DOI: 10.3350/cmh.2022.0318. View

Kim M, Han K, Yoo J, Hwang S, Ahn S . Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver. Aliment Pharmacol Ther. 2021; 55(1):97-107. DOI: 10.1111/apt.16706. View

Lazarus J, Newsome P, Francque S, Kanwal F, Terrault N, Rinella M . Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023; 79(3):E93-E94. DOI: 10.1097/HEP.0000000000000696. View

Fan J, Kim S, Wong V . New trends on obesity and NAFLD in Asia. J Hepatol. 2017; 67(4):862-873. DOI: 10.1016/j.jhep.2017.06.003. View

Shiha G, Korenjak M, Casanovas T, Mooney V, Sigurdardottir S, Koulla Y . MAFLD 2022: An ELPA/ALPA/EASO-ECPO joint statement on disease stigma. J Hepatol. 2022; 77(6):1717-1719. DOI: 10.1016/j.jhep.2022.08.027. View

Ko E, Yoon E, Won Jun D . Risk factors in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2022; 29(Suppl):S79-S85. PMC: 10029944. DOI: 10.3350/cmh.2022.0398. View

Laurel Yoon E, Won Jun D . Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology. Clin Mol Hepatol. 2023; 29(2):371-373. PMC: 10121300. DOI: 10.3350/cmh.2023.0086. View

Yang M, Wei L . Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia. Liver Int. 2022; 42(9):1981-1990. DOI: 10.1111/liv.15252. View

10.

Lee Y, Moon H, Lee J, Cho E, Yu S, Kim Y . Association of Metabolic Risk Factors With Risks of Cancer and All-Cause Mortality in Patients With Chronic Hepatitis B. Hepatology. 2020; 73(6):2266-2277. DOI: 10.1002/hep.31612. View

11.

Song S, Lai J, Wong G, Wong V, Yip T . Can we use old NAFLD data under the new MASLD definition?. J Hepatol. 2023; 80(2):e54-e56. DOI: 10.1016/j.jhep.2023.07.021. View

12.

Carol M, Perez-Guasch M, Sola E, Cervera M, Martinez S, Juanola A . Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. PLoS One. 2022; 17(4):e0265153. PMC: 8986095. DOI: 10.1371/journal.pone.0265153. View

13.

Karlsen T, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E . The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2021; 399(10319):61-116. DOI: 10.1016/S0140-6736(21)01701-3. View

14.

Joo S, Kim W . Interaction between sarcopenia and nonalcoholic fatty liver disease. Clin Mol Hepatol. 2022; 29(Suppl):S68-S78. PMC: 10029947. DOI: 10.3350/cmh.2022.0358. View

15.

Eslam M, Sanyal A, George J . MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158(7):1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312. View

16.

Wong Y, Nguyen V, Yang H, Li J, Le M, Wu W . Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis. Clin Mol Hepatol. 2023; 29(3):705-720. PMC: 10366810. DOI: 10.3350/cmh.2023.0004. View

17.

Zhang S, Mak L, Yuen M, Seto W . Screening strategy for non-alcoholic fatty liver disease. Clin Mol Hepatol. 2022; 29(Suppl):S103-S122. PMC: 10029948. DOI: 10.3350/cmh.2022.0336. View

18.

Graupera I, Thiele M, Serra-Burriel M, Caballeria L, Roulot D, Wong G . Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. Clin Gastroenterol Hepatol. 2021; 20(11):2567-2576.e6. DOI: 10.1016/j.cgh.2021.12.034. View